Clinical study on meropenem and imipenem/cilastatin in treatment of respiratory tract infections
- VernacularTitle:美罗培南和亚胺培南/西司他丁治疗呼吸道细菌感染的临床研究
- Author:
Yuming SONG
;
Jianjun ZHAO
;
Lu SUN
- Publication Type:Journal Article
- From:
Chinese Pharmaceutical Journal
2001;(2):128-129
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the availability and safety of a new carbapenem meropenem.METHODS The randomized study was conducted in 60 patients with respiratory tract infections.They were divided into two groups:meropenem or imipenem/cilastatin.RESULTS The cure rate,effective rate and bacterial clearance rate for meropenem were 80.0%,93.3%,92.3%,respectively and for those of imipenem/cilastatin were 76.7%,90.0% and 91.3%,respectively.The rate of adverse reactions for both meropenem/cilastatin was 3.3%.CONCLUSION Meropenem appeared to be a highly effective and safe agent in treatment of respiratory tract infections.Its efficacy and safety are similar to that of imipenem/cilastatin.
